Please ensure Javascript is enabled for purposes of website accessibility

Why Surface Oncology Is Flying Higher After Hours Today

By Eric Volkman - Mar 30, 2021 at 6:11PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Its pancreatic cancer drug gets a nod from the FDA.

What happened

Regulatory approvals are big wins for biotech companies. It is no different for cancer drug specialist Surface Oncology (SURF -2.54%), the shares of which were up nearly 13% in early after-hours trading Tuesday following an important nod from the U.S. Food and Drug Administration (FDA).

So what

After market close, Surface Oncology announced that the regulator granted the company's SRF617 orphan drug designation for the treatment of pancreatic cancer.   

A medical professional using a microscope.

Image source: Getty Images.

Orphan drugs are medicines that treat extremely rare conditions; typically, this means they affect less than 200,000 people in the U.S. Because these afflictions are rare, the government provides incentives to biotechs and others developing products for them. These include tax credits for the costs of clinical trials, marketing exclusivity, and access to grants.

With these in its pocket, a company like Surface Oncology can do extremely well as the monopoly provider of a successful treatment for a rare condition.

SRF617, one of the biotech's three wholly owned pipeline drugs, is still undergoing phase 1 clinical study. So far, though, the results have been encouraging enough for the FDA to grant it the new status.

Now what

According to American Cancer Society estimates, around 60,430 people will be diagnosed with pancreatic cancer this year, and the disease will claim roughly 48,220 lives. Those numbers starkly illustrate the need for a cutting-edge, effective therapy to help beat the disease. Investors clearly have high hopes that SRF617 will ultimately prove to be that drug.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Surface Oncology, Inc. Stock Quote
Surface Oncology, Inc.
SURF
$1.92 (-2.54%) $0.05

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
331%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/21/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.